Fatty acid amide hydrolase inhibitors - progress and potential

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 5, 2011, Pages 545-558

  Khanna, Ish K ^a   Alexander, Christopher W ^b  

^a Kareus Therapeutics SA   (United States)

^b KENNESAW STATE UNIVERSITY   (United States)

Author keywords

Anandamide; Cannabinoid; Endocannabinoid; FAAH inhibitor; Fatty acid amide hydrolase; N acyl ethanolamines; N arachidonylethanolamine; N oleoylethanolamide; Palmitoylethanolamine

Indexed keywords

ALPHA KETOHETEROCYCLE DERIVATIVE; ANANDAMIDE; AZETIDINONE DERIVATIVE; BORONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CARBAMIC ACID DERIVATIVE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DICLOFENAC; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; HETEROCYCLIC COMPOUND; HYDANTOIN DERIVATIVE; LYSINE; N OLEOYLETHANOLAMINE; PALMIDROL; PIPERIDINE DERIVATIVE; SERINE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALLODYNIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; APPETITE; ARTICLE; BINDING AFFINITY; CATABOLISM; CATALYSIS; CHEMICAL BOND; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; EDEMA; ENTERITIS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME STRUCTURE; GENE DELETION; GLOBUS PALLIDUS; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; HOT PLATE TEST; HUMAN; HYDROGEN BOND; HYDROLYSIS; HYDROPHOBICITY; HYPERALGESIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOPHILICITY; MEMORY; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR SIZE; MOTOR COORDINATION; MUTAGENESIS; NERVE COMPRESSION; NEUROPATHIC PAIN; NONHUMAN; NUCLEOPHILICITY; PAIN; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH IRRITATION; STRUCTURE ACTIVITY RELATION; VISCERAL PAIN;

EID: 79959983494     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711796234989     Document Type: Article

References (126)

1. Hwang, J.; Adamson, C; Butler, D.; Janero, D.R.; Makriyannis, A.; Bahr, B.A. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci., 2010, 86, 615-623.
2. 9- etrahydrocannabinol and anandamide administration. Neuropsycopharmacology, 2010, 35, 1775-1787.
3. Sun, Y.; Alexander, S.P.H.; Garle, M.J.; Gibson, C.L.; Hewitt, K.; Murphy, S.P.; Kendall, D.A.; Bennett, A.J. Cannabinoid activation of PPARa: a novel neuroprotective mechanism. Br. J. Pharmacol, 2007, 152, 734-743.
4. O'Sullivan, S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors, Br. J. Pharmacol, 2007, 152, 576-582.
5. Ross, R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci., 2009, 30, 156-163.
6. Cravatt, B.F.; Giang, D.K.; Mayfield, S.P.; Boger, D.L.; Lerner, R.A.; Gilula, N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature, 1996, 384, 83-87.
7. Ho, W-S.V.; Barret, D.A.; Randall, M.D.'Entourage' effects of N- palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol, 2008, 155, 837-846.
8. Bari, M.; Battista, N.; Fezza, F.; Gasperi, V.; Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. Mini-Rev. Med. Chem., 2006, 6, 257-268.
9. Cravatt, B.F.; Demarest, K.; Patricelli, M.P.; Bracey, M.H.; Glang, D.K.; Martin, B.R.; Lichtman, A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 2001, 98, 9371-9376.
10. Pacher, P.; Bátkai, S.; Osei-Hyiaman, D.; Offertáler, L.; Liu, J.; Harvey-White, J.; Brassai, A.; Járai, Z.; Cravatt, B.F.; Kunos, G. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol, 2005, 289, H533-H541.
11. Lichtman, A.H.; Shelton, C.C.; Advani, T.; Cravatt, B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor- mediated phenotypic hypoalgesia. Pain, 2004, 109, 319-327.
12. Chang L.; Luo, L.; Palmer, J.A.; Sutton, S.; Wilson, S.J.; Barbier A.J.; Breitenbucher J.G.; Chaplan, S.R.; Webb, M. Inhibition of fatty acid amide produces analgesia by multiple mechanisms. Br. J. Pharmcol, 2006, 148, 102-113.
13. Mackie, K. Cannabinoid receptors: what they are and what they do. J. Neuroendocrinol., 2008, 20(Suppl.1), 10-14.
14. Gobbi, G.; Bambico, F.R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M.G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S.R.; Cuomo, V.; Piomelli, D. Antidepres-sant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl Acad. Sci. USA, 2005, 102, 18620-18625.
15. Justinova, Z.; Mangieri, R.A.; Bortolato, M.; Svetlana, I.C.; Mukhin, A.G.; Clapper, J.R.; King, A.R.; Redhi, G.H.; Yasar, S.; Piomelli, D.; Goldberg, S.R. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry, 2008, 64, 930-937.
16. Kathuria, S.; Gaetani, S.; Fegley, D.; Valiño, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 2003, 9, 76-81.
17. Deng, H. Recent advances in the discovery and evaluation of fatty acid amide hydrolases inhibitors. Expert Opin. Drug Discov., 2010, 5, 961-993.
18. Petrosino, S.; Di Marzo, V. FAAH and MAGL inhibitors; therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs, 2010, 11, 51-62.
19. Ahn, K.; Johnson, D.S.; Cravatt, B.F. Fatty acid amide hydrolase as a potential therapeutic target for treatment of pain and CNS disorders. Expert Opin. Drug Discov., 2009, 4, 763-784.
20. Seierstad, M.; Breitenbucher, J.G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J. Med. Chem., 2008, 51, 7327-7343.
21. Pillarisetti, S.; Alexander, C.W.; Khanna, I. Pain and beyond: Fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular disease and metabolic diseases. Drug Disc. Today, 2009, 14, 1098-1111.
22. Kaczocha, M.; Glaser, S.T.; Deutsch, D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. USA, 2009, 106, 6375-6380.
23. Desarnaud, F.; Cadas, H.; Piomelli, D. Anandamide amidohydrolase activity in rat brain microsomes. J. Biol. Chem., 1995, 270, 6030-6035.
24. Matsuda, S.; Kanemitsu, N.; Nakamura, A.; Mimura, Y.; Ueda, N.; Kurahashi, Y.; Yamamoto, S. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp. Eye Res., 1997, 64, 707-711.
25. Watanabe, K.; Ogi, H.; Nakamura, S.; Kayano, Y.; Matsunaga, T.; Yoshimura, H.; Yamamoto, I. Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sci., 1998, 62, 1223-1229.
26. Maccarrone, M.; De Felici, M.; Bari, M.; Klinger, F.; Siracusa, G.; Finazzi-Agrò, A. Down-regulation of anandamide hydrolases in mouse uterus by sex hormones. Eur. J. Biochem., 2000, 267, 2991-2997.
27. Bobrov, M.Y.; Shevchenko, V.P.; Yudushkin, I.A.; Rogov, S.I.; Remov, M.N.; Fomina-Ageeva, E.V.; Gretskaya, N.M.; Nagaev, I.Y.; Kuklev, D.V.; Bezuglov, V.V. Hydrolysis of anandamide and eicosapentaenoic acid ethanolamide in mouse splenocytes. Biochemistry (Mosc.), 2000, 65, 615-619.
28. Mouslech, Z.; Vasiliki, V. Endocannabinoid system: an overview of its potential in current medical practice. Neuroendocrinol. Lett., 2009, 30, 153-274.
29. Wei, B.Q.; Mikkelsen, T.S.; McKinney, M.K.; Lander, E.S.; Cravatt, B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem., 2006, 281, 36569-36578.
30. Minkkilä A.; Savinainen, J.R.; Käsnänen, H.; Xhaard, H.; Nevalainen, T.; Laitinen, J.T.; Poso, A.; Leppänen, J.; Saario, S.M. Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. ChemMedChem, 2009, 4, 1253-1259.
31. Minkkilä, A.; Saario, S.M.; Nevalainen, T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr. Top. Med. Chem., 2010, 10, 828-858.
32. Lambert, D.M.; Fowler, C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem., 2005, 48, 5059-5087.
33. Jhaveri, M.D.; Richardson, D.; Chapman, V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol, 2007, 152, 624-632.
34. McKinney, M.K.; Cravatt, B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem., 2005, 74, 411-432.
35. Patricelli, M.P.; Cravatt, B.F. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry, 1999, 38, 14125-14130.
36. McKinney, M.K.; Cravatt, B.F. Evidence for distinct roles in catalysis for residues for the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J. Biol. Chem., 2003, 278, 37393-37399.
37. Mileni, M.; Garfunkle, J.; Ezzili, C; Kimball, F.S.; Cravatt, B.F.; Stevens, R.C.; Boger, D.L. X-ray crystallographic analysis of a-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J. Med. Chem., 2010, 53, 230-240.
38. Mileni, M.; Garfunkle, J.; DeMartino, J.K.; Cravatt, B.F.; Boger, D.L.; Stevens, R.C. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by a-ketoheterocycle inhibitors revealed from cocrystal structures. J. Am. Chem. Soc, 2009, 131, 10497-10506.
39. Ahn, K.; Johnson, D.S.; Mileni, M.; Beidler, D.; Long, J.Z.; McKinney, M.K.; Weerapana, E.; Sadagopan, N.; Liimatta, M.; Smith, S.E.; Lazerwith, S.; Stiff, C; Kamtekar, S.; Bhattacharya, K.; Zhang, Y.; Swaney, S.; Becelaere, K.V.; Stevens, R.C; Cravatt, B.F. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol, 2009, 16, 411-420.
40. Mileni, M.; Johnson, D.S.; Wang, Z.; Everdeen, D.S.; Liimatta, M.; Pabst, B.; Bhattacharya, K.; Nugent, R.A.; Kamtekar, S.; Cravatt, B.F.; Ahn, K.; Stevens, R.C. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc. Natl. Acad. Sci. USA, 2008, 105, 12820-12824.
41. Mileni, M.; Kamtekar, S.; Wood, D.C.; Benson, T.E.; Cravatt, B.F.; Stevens, R.C. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J. Mol Biol, 2010, 400, 743-754.
42. Di Zhang, A.S.; Kolasa, T.; Bhatia, P.; Zheng, G.Z.; Patel, M.; Lannoye, G.S.; Richardson, P.; Stewart, A.; Rogers, J.C.; Brioni, J.D.; Surowy, C.S. Fatty acide amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology, 2007, 52, 1095-1105.
43. Alexander, J.P.; Cravatt, B.F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol, 2005, 12, 1179-1187.
44. Bisogno, T.; De Petrocellis, I.; Di Marzo, V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr. Pharm. Des., 2002, 8, 533-547.
45. Deutsch, D.G.; Omeir, R; Arreaza, G.; Salehani, D.; Prestwich, G.D.; Huang, Z.; Howlett, A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol, 1997, 53, 255-260.
46. De Petrocellis, L.; Bisogno, T.; Maccarrone, M.; Davis, J.B.; Finnazzi-Argò, A.; Di Marzo, V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 2001, 276, 12856-12863.
47. Bisogno, T.; Melck, D.; De Petrocellis, L.; Bobrov, M.Y.; Gretskaya, N.M.; Bezuglov, V.V.; Sitachitta, N.; Gerwick, W.H.; Di Marzo, V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun., 1998, 248, 515-522.
48. Patterson, J.E.; Ollmann, I.R.; Cravatt, B.F.; Boger, D.L.; Wong, C-H.; Lerner, R.A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogeneous sleep-inducing lipid cis-9-octadecenamide. J. Am. Chem. Soc, 1996, 118, 5938-5945.
49. Johnson, D.S.; Stiff, C; Lazerwith, S.E.; Kesten, S.R.; Fay, L.K.; Morris, M.; Beidler, D.; Liimatta, M.B.; Smith, S.E.; Dudley, D.T.; Sadagopan, N.; Bhattachar, S.N.; Kesten, S.J.; Nomanbhoy, T.K.; Cravatt, B.F.; Ahn, K. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med. Chem. Lett, 2011, 2(2), 91-96.
50. Fegley, D.; Gaetani, S.; Duranti, A; Tontini, T.; Mor, M.; Tarzia, G.; Piomelli, D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl-ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther., 2005, 313, 352-358.
51. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P.V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kutharia, S.; Piomelli, D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationship, and molecular modeling studies. J. Med. Chem., 2004, 47, 4998-5008.
52. Kathuria, S.; Gaetani, S.; Fegley, D.; Valiño, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 2003, 9(1), 76-81.
53. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P.V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J. Med. Chem., 2003, 46, 2352-2360.
54. Tarzia, G.; Duranti, A.; Gatti, G.; Piersanti, G.; Tontini, A.; Rivara, S.; Lodola, A.; Pier, V.P.; Mor, M.; Kathuria, S.; Piomelli, D. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem, 2006, 1, 130-139.
55. Labar, G.; Michaux, C. Fatty acid amide hydrolase: from characterization to therapeutics. Chem. Biodivers., 2007, 4, 1882-1902.
56. Mor, M.; Lodola, A.; Rivara, S.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Piersanti, G.; Clapper, J.R.; King, A.R.; Tarzia, G.; Piomelli, D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J. Med. Chem., 2008, 51, 3487-3498.
57. Vacondio, F.; Silva, C.; Lodola, A.; Fioni, A.; Rivara, S.; Duranti, A.; Tontini, A.; Sanchini, S.; Clapper, J.R.; Piomelli, D.; Mor, M.; Tarzia, G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. Chem Med Chem, 2009, 4, 1495-1504.
58. Clapper, J.R.; Vacondio, F.; King, A.R.; Duranti, A.; Tontini, A.; Silva, C.; Sanchini, S.; Tarzia, G.; Mor, M.; Piomelli, D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem, 2009, 4, 1505-1513.
59. Holt, S.; Comelli, F.; Costa, B.; Fowler, C.J. Inhibitors of fatty acid hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol., 2005, 146, 467-476.
60. Jayamanne, A.; Greenwood, R.; Mitchell, V.A.; Aslan, S.; Piomelli, D.; Vaughan, C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol., 2006, 147, 281-288.
61. Haller, V.L.; Cichewicz, D.L.; Welch, S.P. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur. J. Pharmacol., 2006, 546, 60-68.
62. Naidu, P.S.; Booker, L.; Cravatt, B.F.; Lichtman, A.H. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J. Pharmacol. Exp. Ther., 2009, 329, 48-56.
63. Storr, M.A.; Keenan, C.M.; Emmerdinger, D.; Zhang, H.; Yüce, B.; Sibaev, A.; Massa, F.; Buckley, N.E.; Lutz, B.; Göke, B.; Brand, S.; Patel, K. D.; Sharkey, K.A. Targeting endocannabinoid degration protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med., 2008, 86, 925-936.
64. Storr, M.A.; Yüce, B.; Andrews, C.N.; Sharkey, K.A. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil., 2008, 20, 857-868.
65. Russo, R.; LoVerme, J.; La Rana, G.; Compton, T.R.; Parrott, J.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Calignano, A.; Piomelli, D. The fatty acid amide hydrolases inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther., 2007, 322, 236-242.
66. Lichtman, A.H.; Leung, D.; Shelton, C.C.; Saghatelian, A.; Hardouin, C.; Boger, D.L., Cravatt, B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther., 2004, 311, 441-448.
67. Ahn, K.; Johnson, D.S.; Fitzgerald, L.R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E.T.; Nugent, R.A.; Nomanbhoy, T.K.; Alexander, J.P.; Cravatt, B.F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry, 2007, 46, 13019-13030.
68. Abouabdellah, A.; Görlitzer, J.; Hamley, P.; Ravet, A. Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof. WO 2010/010288 A2, January 28, 2010.
69. Abouabdellah, A.; Burnier, P.; Hoornaert, C.; Jeunesse, J.; Puech, F. Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics. US 7,214,798 B2, May 8, 2007.
70. Abouabdellah, A.; Almario Garcia, A.; Hoorneart, C.; Li, A.T. Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as FAAH enzyme inhibitors. WO 2005/090322 A2, September 29, 2005.
71. Abouabdellah, A.; Almario Garcia, A.; Froissant, J.; Hoornaert, C. Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics. WO 2005/077898 A1, August 25, 2005.
72. Abouabdellah, A.; Bas, M.; Dargazanli, G.; Hoornaert, C.; Li, A.T.; Medaisko, F. Derivatives of dioxane-2-alkyl-carbamates, preparation thereof and application thereof in therapeutics. US 7,119,116 B2, October 10, 2006.
73. An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients (FIDELIO). http://www.clinicaltrials.gov/ct2/show/NCT00822744?term=FIDELIO&rank=1 (accessed February 10, 2010).
74. Sanofi-Aventis (Half Year Financial Report), http://en.sanofi-aventis.com/investors/investors.asp (accessed January 17, 2011).
75. Sit, S.Y.; Conway, C.; Bertekap, R.; Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett., 2007, 17, 3287-3291.
76. Sit, S.Y.; Conway, C.M.; Xie, K.; Bertekap, R.; Bourin, C.; Burris, K.D. Oxime carbamate-discovery of a series of novel FAAH inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1272-1277.
77. Myllymäki, M.J.; Käsnänen, H.; Kataja, A.O.; Lahtela-Kakkonen, M.; Saario, S.M.; Poso, A.; Koskinen, A.M.P. Chiral 3-(4, 5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: insight into FAAH enantioselectivity by molecular docking and interaction fields. Eur. J. Med. Chem., 2009, 44, 4179-4191.
78. Minkkilä, A.; Myllymäki, M.J.; Saario, S.M.; Castillo-Melendez, J.A.; Koskinen, A.M.P.; Fowler, C.J.; Leppänen, J.; Nevalainen, T. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur. J. Med. Chem., 2009, 44, 2994-3008.
79. Alexander, J.P.; Cravatt, B.F. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J. Am. Chem. Soc., 2006, 128, 9699-9704.
80. Apodaca, R.; Breitenbucher, J.G.; Pattabiraman, K.; Seierstad, M.; Xiao, W. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase. WO 2006/074025, July 13, 2006.
81. Apodaca, R.; Breitenbucher, J.G.; Hawryluk, N.A.; Jones, W.M.; Keith, J.M.; Merit, J.E.; Tichenor, M.S.; Timmons, A.K. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase. WO 2008/153752, December 18, 2008.
82. Keith, J.M.; Apodaca, R.; Xiao, W.; Seierstad, M.; Pattabiraman, K.; Wu, J.; Webb, M.; Karbarz, M.J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C-S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J.G. Thiadioazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett., 2008, 18, 4838-4843.
83. Karbarz, M.J.; Luo, L.; Chang, L.; Tham, C-S.; Palmer, J.A.; Wilson, S.J.; Wennerholm, M.L.; Brown, S.M.; Scott, B.P.; Apodaca, R.L.; Keith, J.M.; Wu, J.; Breitenbucher, J.G.; Chaplan, S.R.; Webb, M. Biochemical and biological properties of 4-(3- phenyl-[1,2,4]thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth. Analg., 2009, 108, 316-329.
84. Johnson, D.S. Discovery of highly selective urea FAAH inhibitors that reduce inflammatory pain. Presented at the World Pharmaceutical Congress meeting: Drug Discovery Innovation Summit (Targeting Pain with Novel Therapeutics), Philadelphia, PA, USA June 9-11, 2009.
85. Wang, J.L.; Bowen, S.J.; Schweitzer, B.A.; Madsen, H.M.; McDonald, J.; Pelc, M.J.; Tenbrink, R.E.; Beidler, D.; Thorarensen, A. Structure based design of novel irreversible FAAH inhibitors. Biorg. Med. Chem. Lett., 2009, 19, 5970-5974.
86. Johnson, D.S.; Ahn, K.; Keston, S.; Lazerwith, S.E.; Song, Y.; Morris, M.; Fay, L.; Gregory, T.; Stiff, C; Dunbar, Jr. J.B.; Liimatta, M.; Beidler, D.; Smith, S.; Nomanbhoy, T.K.; Cravatt, B.F. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett., 2009, 19, 2865-2869.
87. Johnson, D.S. Targeting selective fatty acid amide hydrolase (FAAH) inhibitors for treatment of inflammatory pain. Presented at the World Pharmaceutical Congress: Drug Discovery Innovation Summit (Targeting Pain with Novel Therapeutics), Philadelphia, PA, USA May 2008.
88. A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers. http://www.clinicaltrials.gov/ct2/show/NCT00836082?term=FAAH&rank=2 (accessed February 04, 2010).
89. A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee. http://www.clinicaltrials.gov/ct2/show/NCT00981357?term=FAAH&rank=1 (accessed February 10, 2010).
90. Hart, T.; Macias, A.T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Dokurno, P.; Francis, G.; Gibbons, B.; Haymes, T.; Kennett, G.; Lightowler, S.; Mansell, H.; Matassova, N.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Walls, S.; Wong, M.; Roughley, S. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg. Med. Chem. Lett., 2009, 19, 4241-4244.
91. V158866. http://www.vernalis.com/development/cns/v158866 (accessed January 20, 2011).
92. Watanabe, K.; Kayano, Y.; Matsunaga, T.; Yamamoto, I.; Yoshimura, H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol. Pharm. Bull, 1996, 19, 1109-1111.
93. Bisogno, T.; Hanus, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D.E.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol, 2001, 134, 845-852.
94. Fowler, C.J.; Börjesson, M.; Tiger, G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br. J. Pharmacol, 2000, 131, 498-504.
95. Fowler, C.J.; Tiger, G.; Stenström, A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J. Pharmacol. Exp. Ther., 1997, 283, 729-734.
96. Patel, S.; Wohfeil, E.R.; Rademacher, D.J.; Carrier, E.J.; Perry, L.J.; Kundu, A.; Falck, J.R.; Nithipatikom, K.; Campbell, W.B.; Hillard, C.J. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br. J. Pharmacol, 2003, 139, 1005-1013.
97. Maccarrone, M. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr. Pharm. Design, 2006, 12, 759-772.
98. Boger, D.L.; Sato, H.; Lerner, A.E.; Hedrick, M.P.; Fecik, R.A.; Miyauchi, H.; Wilkie, G.D.; Austin, B.J.; Patricelli, M.P.; Cravatt, B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA, 2000, 97, 5044-5049.
99. Boger, D.L; Miyauchi, H.; Du, W.; Hardouin, C; Fecik, R.A.; Cheng, H.; Hwang, I.; Hedrick, M.P.; Leung, D.; Acevedo, O.; Guimaraes, C.R.W.; Jorgensen, W.L.; Cravatt, B.F. Discovery of a potent, selective, and efficacious class of reversible a-ketoheterocycle inhibitors of fatty acid amide hydrolases effective as analgesics. J. Med. Chem., 2005, 48, 1849-1856.
100. Garfunkle, J.; Ezzili, C; Rayl, T.J.; Hochstatter, D.G.; Hwang, I.; Boger, D.L. Optimization of the central heterocycle of a-ketoheterocycle inhibitors of fatty acid amide hydrolase. J. Med. Chem., 2008, 51, 4392-4403.
101. Kimball, F.S.; Romero, F.A.; Ezzili, C; Garfunkle, J.; Rayl, T.J.; Hochstatter, D.G.; Hwang, I.; Boger, D.L. Optimization of a-ketoheterocycle inhibitors of fatty acid amide hydrolase. J. Med. Chem., 2008, 51, 937-947.
102. Timmons, A.; Seierstad, M.; Apodaca, R.; Epperson, M.; Pippel, D.; Brown, S.; Chang, L.; Scott, B.; Webb, M.; Chaplan, S.R.; Breitenbucher, J.G. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett., 2008, 18, 2109-3113.
103. Urbach, A.; Muccioli, G.G.; Stern, E.; Lambert, D.M.; Marchand-Brynaert, J. 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4163-4167.
104. Feledziak, M.; Michaux, C; Urbach, A.; Labar, G.; Muccioli, G.G.; Lambert, D.M.; Marchand-Brynaert, J. P-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase. J. Med. Chem., 2009, 52, 7054-7068.
105. Muccioli, G.G.; Wouters, J.; Scriba, G.K.E.; Poppitz, W.; Poupaert, J.H.; Lambert, D.M. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: New templates among CB1 cannabinoid receptor inverse agonists. J. Med. Chem., 2005, 48, 7486-7490.
106. Muccioli, G.G.; Fazio, N; Scriba, G.K.E.; Poppitz, W.; Cannata, F.; Poupaert, J.H.; Wouters, J.; Lambert, D.M. Substituted 2-thioxoimidiazolidin-4-ones and imidiazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J. Med. Chem., 2006, 49, 417-425.
107. Wang, X.; Sarris, K.; Kage, K.; Zhang, D.; Brown, S.P.; Kolasa, T.; Surowy, C; El Kouhen, OF.; Muchmore, S.W.; Brioni, J.D.; Stewart, A.O Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J. Med. Chem., 2009, 52, 170-180.
108. Adams, J.; Behnke, M.L.; Castro, A.C.; Evans, C.A.; Grenier, L.; Grogan, M.J.; Liu, T.; Snyder, D.A.; Tibbitts, T.T. Boronic acids and esters as inhibitors of fatty acid amide hydrolase. WO 2008/063300, May 29, 2008.
109. Behnke, M.L.; Castro, A.C.; Evans, C.A.; Grenier, L.; Grogan, M.J.; Liu, T.; Snyder, D.A.; Tibbitts, T.T. Inhibitors of fatty acid amide hydrolase. WO 2009/126691 A1, October 15, 2009.
110. Minkkilä, A; Saario, S.M.; Käsnänen, H; Leppänen, J.; Poso, A; Nevalainen, T. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolases. J. Med. Chem., 2008, 51, 7057-7060.
111. Kelly, M.G.; Kincaid, J.; Gowlugari, S.; Kaub, C. Compounds useful as FAAH modulators and uses thereof. WO 2009/011904, January 22, 2009.
112. Kaub, C; Gowlugari, S.; Kincaid, J.; Johnson, R.J.; O'Mahony, D.J.R.; Estiarte-Martinez, M.; Duncton, M. Preparation of benzooxazole compounds as FAAH modulators. WO 2010/039186 A2, 2010.
113. Apodaca, R.; Breitenbucher, J.G.; Chambers, A.L.; Deng, X.; Hawryluk, N.A.; Keith, J.M.; Mani, N.S.; Merit, J.E.; Pierce, J.M.; Seierstad, M.; Xiao, W. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase. WO 2009/105220, August 27, 2009.
114. Chobanian, H; Lin, L.S.; Liu, P.; Chioda, M.D.; Devita, R.J.; Nargund, R.P.; Guo, Y. Oxazole derivatives useful as inhibitors of FAAH. WO 2010/017079 A1, February 11, 2010.
115. Lin, L.S.; Chioda, M.D.; Liu, P.; Nargund, R.P. Preparation of imidazole derivatives useful as inhibitors of FAAH. WO 2009/151991 A1, 2009.
116. Micale, V.; Cristino, L.; Tamburella, A.; Petrosino, S.; Leggio, G.M.; Drago, F.; Di Marzo, V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology, 2009, 34, 593-606.
117. Morera, E.; De Petrocellis, L.; Morera, L.; Moriello, A.S.; Ligresti, A.; Nalli, M.; Woodward, D.F.; Di Marzo, V.; Ortar, G. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg. Med. Chem., 2009, 19, 6806-6809.
118. Forster, L.; Ludwig, J.; Kaptur, M.; Bovens, S.; Elfringhoff, A.S.; Holtfrerich, A.; Lehr, M. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2a and fatty acid amide hydrolase. Bioorg. Med. Chem., 2010, 18, 945-952.
119. Bartolini, W.; Cali, B.M.; Chen, B.; Chien, Y-T.; Currie, M.G.; Milne, G.T.; Pearson, J.P.; Talley, J.J.; Yang, J.J.; Zimmerman, C; Kim, C; Sprott, K; Barden, T.; Lundigran, R.; Mermerian, A. Useful indole compounds. WO 2007/070892, June 21, 2007.
120. Bartolini, W.; Cali, B.M.; Chen, B.; Chien, Y-T.; Currie, M.G.; Milne, T.G.; Pearson, J.P.; Talley, J.J.; Zimmerman, C. COX-2 and FAAH Inhibitors. WO 2005/002525, January 13, 2005.
121. Talley, J.J.; Sprott, K; Pearson, J.P.; Milne, G.T.; Schairer, W.; Yang, J.; Kim, C; Barden, T.; Lundrigan, R.; Mermerian, A.; Currie, M.G. Indole compounds for treating pain, inflammation and other conditions. WO 2008/019357, February 14, 2008.
122. Study to evaluate efficacy and safety of IW-6118 in patients undergoing third molar extraction. http://www.clinicaltrials.gov/ct2/show/NCT01107236?term=IW-6118&rank=1 (accessed January 18, 2011).
123. Onnis, V.; Congiu, C; Björklund, E.; Hempel, F.; Söderström, E.; Fowler, C.J. Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolases inhibitors. J. Med. Chem., 2010, 53, 2286-2298.
124. Infinity initiates clinical development of its fourth drug candidate and announces 2009 financial results. http://investor.ipi.com/release detail.cfm? ReleaseID=444213 (accessed February 19, 2010).
125. Infinity Pharmaceuticals-FAAH. http://www.infi.com/discovery-FAAH.html (accessed January 21, 2011).
126. Sun, X.; Wang, H; Okabe, M.; Mackie, K; Kingsley, P.J.; Marnett, L.J.; Cravatt, B.F.; Dey, S. K. Genetic loss of FAAH compromises male fertility in mice. Biol. Reprod., 2009, 80, 235-242.